Genzyme open to selling noncore businesses

Genzyme (NASDAQ: GENZ) is open to selling off some of its noncore businesses, CEO Henri Termeer (photo) said Tuesday at the Health Blog HQ, according to the Wall Street Journal Health Blog. The company will brief analysts and investors about its more peripheral businesses at a May 6 meeting in Boston, when it also will reveal details about its individual operations. Report

Suggested Articles

Half of patients in an early trial of Allogene's off-the-shelf CAR-T cells for lymphoma who received a higher dose of its antibody ALLO-647 responded.

Takeda is tossing out a Shire pipeline med after it couldn't find a buyer.

Ipsen's new hire arrives at a company reeling from a torrent six months that have crushed hopes for its $1 billion bet on a rare disease drug.